Enliven Therapeutics Stock Probability of Future Stock Price Finishing Over 25.41
| ELVN Stock | 25.41 1.06 4.35% |
Enliven |
Enliven Therapeutics Target Price Odds to finish over 25.41
The tendency of Enliven Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 25.41 | 90 days | 25.41 | about 52.79 |
Based on a normal probability distribution, the odds of Enliven Therapeutics to move above the current price in 90 days from now is about 52.79 (This Enliven Therapeutics probability density function shows the probability of Enliven Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.07 suggesting Enliven Therapeutics market returns are highly reactive to returns on the market. As the market goes up or down, Enliven Therapeutics is expected to follow. Additionally Enliven Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Enliven Therapeutics Price Density |
| Price |
Predictive Modules for Enliven Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Enliven Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Enliven Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Enliven Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Enliven Therapeutics is not an exception. The market had few large corrections towards the Enliven Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Enliven Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Enliven Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.01 | |
β | Beta against Dow Jones | 1.07 | |
σ | Overall volatility | 2.57 | |
Ir | Information ratio | -0.0017 |
Enliven Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Enliven Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Enliven Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Net Loss for the year was (71.58 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Enliven Therapeutics generates negative cash flow from operations | |
| Enliven Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Disposition of 526 shares by Kintz Samuel of Enliven Therapeutics at 27.5371 subject to Rule 16b-3 |
Enliven Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Enliven Stock often depends not only on the future outlook of the current and potential Enliven Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Enliven Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 35.5 M | |
| Cash And Short Term Investments | 253.1 M |
Enliven Therapeutics Technical Analysis
Enliven Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Enliven Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Enliven Therapeutics. In general, you should focus on analyzing Enliven Stock price patterns and their correlations with different microeconomic environments and drivers.
Enliven Therapeutics Predictive Forecast Models
Enliven Therapeutics' time-series forecasting models is one of many Enliven Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Enliven Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Enliven Therapeutics
Checking the ongoing alerts about Enliven Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Enliven Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Net Loss for the year was (71.58 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Enliven Therapeutics generates negative cash flow from operations | |
| Enliven Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Disposition of 526 shares by Kintz Samuel of Enliven Therapeutics at 27.5371 subject to Rule 16b-3 |
Check out Enliven Therapeutics Backtesting, Enliven Therapeutics Valuation, Enliven Therapeutics Correlation, Enliven Therapeutics Hype Analysis, Enliven Therapeutics Volatility, Enliven Therapeutics History as well as Enliven Therapeutics Performance. To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enliven Therapeutics. If investors know Enliven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enliven Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.89) | Return On Assets (0.21) | Return On Equity (0.31) |
The market value of Enliven Therapeutics is measured differently than its book value, which is the value of Enliven that is recorded on the company's balance sheet. Investors also form their own opinion of Enliven Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Enliven Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enliven Therapeutics' market value can be influenced by many factors that don't directly affect Enliven Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enliven Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enliven Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enliven Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.